NPS Pharmaceuticals — Merger or Acquisition (March 2003)
11 slides from NPS Pharmaceuticals's merger presentation, Mar 18, 2003
Slide 1: Science, Pipeline, Products: Creating a Biotechnology Leader
Science, Pipeline, Products: Creating a Biotechnology Leader
Slide 2: To Build a Sustainable Top-Tier Biotech Based On:
To Build a Sustainable Top-Tier Biotech Based On: • A deep, diversified and sustainable pipeline • A clearly defined pathway to profitability • A fully integrated infrastructure and stable financial position
Slide 3: Platform Technologies and Commercialization
Platform Commercialization Technologies Preclinical Phase I Phase II Phase Ill & Manufacturing * PEGylation * SCA Projects + Single-Chain + PEG- Cytoxics Antibodies + PEGANTRON + Inhaled Leuprolide + ABELCET * ADAGEN + ONCASPAR. + DEPOCYT NPS mm ENZON
Slide 4: The New Entity
The New Entity
Slide 5: Pipeline, Products & Technologies
Pipeline, Products & Technologies
Slide 6: ABELCET, ONCASPAR, DEPOCYT, ADAGEN
• ABELCET ® • ONCASPAR ® • DEPOCYT ® • ADAGEN ®
Slide 7: PREOS (Cinacalcet HCl)
PREOS TM Cinacalcet HCI
Slide 8: Market opportunity (U.S.)
• Market opportunity (U.S.) — Primary HPT 500,000 patients — Secondary HPT 280,000 dialysis patients — Secondary HPT 800,000 predialysis patients
Slide 9: Operational Overview
Operational Overview
Slide 10: Locations
Locations Manufacturing: Indianapolis, IN Research: /Toronto, Canada _ Manufacturing: Toronto, Canada Research: Piscataway, NJ Manufacturing: South Plainfield, NJ Headquarters: Research: Bridgewater, NU Salt Lake City, Utah
Slide 11: Science, Pipeline, Products: Creating a Biotechnology Leader
Science, Pipeline, Products: Creating a Biotechnology Leader
NPS Pharmaceuticals — Merger or Acquisition (March 2003) on 6ix